In particular, studies involving resistant HCC cell lines [17], tumor tissue materials [18] or serum derived from the patients [19] revealed that sorafenib resistance is associated with the upregulation of several signaling pathways, such as Akt S473 phosphorylation [20], the mammalian target of rapamycin (mTOR) pathway [21], and epithelial-to-mesenchymal transition (EMT) [22]. This evidence concerns the gene MTOR and neoplasm.